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Abstract  
Background: IgA nephropathy (IgAN) is a microcosm of glomerular lesions. Some histologic lesions are 
irreversible and progress toward obliteration of glomerular capillaries. Others are acute inflammatory 
processes potentially susceptible to reversal by means of immunosuppressive therapies. Methods: The 
effects of a combined schedule of steroids and mycophenolate mofetil (MMF) was prospectively examined 
in a subset of IgAN patients with acute inflammatory histologic changes associated with proteinuria (mean 
2,400 mg/day, range 1,130-5,250), hematuria (76 red cells per high-power microscopic field, range 30-100) 
and renal failure (serum creatinine 1.6 mg/dL, range 1.2-2.9). Patients had diffuse mesangial proliferation 
with at least 10% florid crescents, mild to moderate degrees of glomerular sclerosis and interstitial changes, 
and both mesangial and capillary deposition of immunoreactants at immunofluorescence. Treatment 
consisted of 3 pulses of methylprednisolone (15 mg/kg) followed by oral prednisone (0.8 mg/ kg body 
weight, tapered until discontinuation within 4 months) and MMF 2 g for 6 months. Results: Serum 
creatinine, proteinuria and microscopic hematuria significantly dropped at 6 months compared with 
baseline values (p=0.01) and remained lower at the end of follow-up 51 months (range 24-90) later (p<0.01, 
for proteinuria and hematuria; p=0.08, for serum creatinine). Conclusion: Therapy with steroids and MMF 
may be considered in a subset of IgAN patients with florid glomerular changes, functional impairment and 
major urinary abnormalities, to prevent subsequent progression toward renal failure. 
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Introduction 
 IgA nephropathy (IgAN) is a microcosm of glomerular lesions (1). Some histologic lesions are irreversible 
and progress toward obliteration of glomerular capillaries. Others are acute phlogistic processes potentially 
susceptible to reversal by means of immunosuppressive therapies. Therefore, it is difficult to identify truly 
homogeneous subsets of patients for treatment trials, especially if the entry criteria are based on a single 
variable such as urinary protein excretion. This could possibility explain in part the conflicting results of 
reports on cytotoxic drugs in these patients (2). Based on the encouraging results of an open 
nonrandomized controlled study on IgAN patients with diffuse mesangial proliferation, florid crescents and 
a mild degree of glomerular sclerosis and tubulointerstitial changes, years ago we proposed administering a 
short course of therapy with prednisone and cyclophosphamide to this particular subset of patients (3). 
With the availability of the a priori less toxic mycophenolate mofetil (MMF), the effects of a combined 
schedule of steroids and MMF were prospectively examined in a subset of IgAN patients with inflammatory 
histologic changes associated with major urinary abnormalities and renal failure. The present prospective 
study reports on the longterm benefits of this scheme, in terms of preservation of renal function and 
changes in urinary abnormalities, in 8 patients who were followed up for 24-90 months (mean 51 months). 
Patients and methods 
Demographic and baseline clinical and histologic features of a sample of 8 patients with at least a 24-month 
followup are summarized in Tables I and II. Proteinuria and serum creatinine were measured by standard 
methods. Glomerular filtration rate was evaluated by the Modification of Diet in Renal Disease (eGFR-
MDRD186) study equation, as recommended by the MDRD Study Group (4). Microscopic hematuria was 
determined at baseline and then every 6 months as a mean of the counts of 5 high-power microscopic 
fields (HPMF) in 3 consecutive evaluations in 7 to 13 days. On average, patients were treated within 1 
month of the renal biopsy. Patients were considered eligible for the treatment if the following inclusion 
criteria were satisfied: presence of diffuse mesangial proliferation with at least 10% florid crescents, and 
mild to moderate degrees of glomerular sclerosis and interstitial changes with immunofluorescence pattern 
of capillary deposits of immunoreactants at the renal biopsy, in combination with major urinary 
abnormalities including proteinuria >1 g/24 hours, and microscopic hematuria >30 red blood cells/HPMF. 
Exclusion criteria included presence of diabetes, severe osteoporosis, severe metabolic syndrome, 
concomitant infection, time from renal biopsy to study entrance more than 8 weeks and age less than 18 or 
more than 80 years. All patients could be classified as M1, S1, E1 and T1-2 according to the Oxford 
classification of IgA nephropathy (5). However, it should be noted that the Oxford classification does not 
shed any light on the predictive value of crescents or the immunofluorescence findings. Treatment 
consisted of 3 pulses of methylprednisolone (15 mg/kg each) followed by oral prednisone (0.8 mg/kg body 
weight, for 2 weeks, 0.6 mg/kg for another 2 weeks, 0.4 mg/kg for an additional 4 weeks, then slowly 
tapered by 5 mg every 2 weeks until discontinuation) and 2 g of MMF for 6 months. All patients were 
hypertensive, and 6 of them had already been treated for at least 3 months with the same dose of 
angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptors blockers when starting with 
immunosuppressive drugs. Differences among study groups were analyzed by multifactorial ANOVA. 
Differences were considered statistically significant when 2-sided p values were <0.05. Statistical analyses 
were carried out using StatView 5.0.1 for Macintosh (SAS Institute, Cary, NC, USA). This study was 
performed according to the local rules for off-label therapy in the Piedmont Region (Northwest Italy). 
Results  
Serum creatinine (baseline levels 1.6 mg/dL, range 1.2-2.9), eGFR-MDRD186 (52.5 ml/min, range 16-86), 
proteinuria (2,420 mg/day, range 1,130-5,250) and even microscopic hematuria (mean baseline count of 3 
separate examinations: 76 red blood cells [RBCs] per HPMF range 28-100) dropped significantly at 6 months 
(creatinine 1.08 mg/ dL, range 0.7-2.1, p=0.01; eGFR-MDRD186 66.9 ml/min, range 24-118, p<0.05; 
proteinuria 845 mg/day, range 150–2,916, p<0.01 and microscopic hematuria 12.25 RBC/HPMF x 400, 0-25, 
p=0.01) compared with pretreatment values. At 6 months, no differences were observed in blood pressure 
(systolic 120 ± 10 mm Hg, diastolic 82 ± 7 mm Hg) and serum albumin (4.1± 0.5 g/dL) compared with 
baseline values (systolic 125 ± 10 mm Hg, diastolic 80 ± 8 mm Hg; serum albumin 3.9 ± 0.5 g/dL). Significant 
differences were observed when baseline data were compared with those determined at the last 
observation 24-90 months (mean 51 months) later in proteinuria (652 mg/day, range 150-2,050) and 
microscopic hematuria (6.9 RBC/HPMF, range 0-25; p<0.01, in both cases), whereas differences in values of 
serum creatinine (1.1 mg/dL, range 0.7-2.0, p=0.08), eGFR-MDRD186 (71 ml/min, range 25-116, p=0.09), 
blood pressure (systolic 120 ± 10 mm Hg, diastolic 75 ± 8 mm Hg, p=0.1) and serum albumin (4.2 ± 0.6 g/dL, 
p=0.9) failed to reach statistically significant levels. Two out of 8 patients (SL and LGM in Tab. II) had serum 
creatinine values higher than their baseline levels (1.4 and 1.8 mg/dL vs. 1.2 and 1.4 mg/dL, respectively). 
General results are summarized in Table III and Figures 1, 2, 3 and 4. Drug side effects were negligible. Only 
1 case, SC, reported transient diarrhea at the beginning of the therapy with MMF, which rapidly resolved 
with probiotic agents.  
Discussion  
Contradictory results have been reported on the use of MMF in IgAN. Initial open studies seemed to 
support its possible role in stabilizing renal function even in high-risk patients (reviewed in (2)). 
Subsequently, 4 randomized studies were published. As first-line therapy, MMF (1-1.5 g/day) was found to 
be superior to steroids in decreasing proteinuria and protecting renal function (6). In contrast, Maes et al 
(7), who compared MMF (2.0 g/day) with placebo, found no significant differences in proteinuria or renal 
function after a 3-year followup. In a third study, Frisch et al (8) found no benefit in “a priori” high-risk 
patients. By contrast, Tang et al reported some definite advantages in MMF as compared with conservative 
treatment (9). The main difficulty in interpreting the results of therapeutic trials in IgAN lies in the wide 
spectrum of the possible histologic lesions, which may be either acute phlogistic and potentially reversible, 
or sclerotic and putatively unresponsive to currently available antiinflammatory or cytotoxic drugs. Male 
prevalence, age at the time of biopsy (>30 years) and moderate to severe intracapillary and extracapillary 
lesions are generally considered prognostically important in IgAN. Crescentic glomerular involvement has 
occasionally been reported as resolving spontaneously, but has more recently been regarded as an 
indicator of unfavorable prognosis even if small and focal (1). Decreased renal function, hypertension and 
proteinuria over 1,000 mg/day were found to be independent risk factors for a poor clinical course of 
disease in several reports. All of these risk factors were often simultaneously present in our study group. 
Tang et al (10) extended their original study by following 40 Chinese patients with established IgAN for 6 
years. All patients were maintained on their angiotensin blockade (30 under ACE-inhibitor and 10 under 
angiotensin receptor blockade) medication, and half were randomized to receive MMF for 6 months. After 
6 years, 11 patients required dialysis (2 from the MMF and 9 from the control group). The authors 
concluded that among Chinese patients with IgAN who had mild histologic lesions and persistent 
proteinuria despite maximal angiotensin blockade, MMF treatment may result in transient and partial 
remission of proteinuria in the short term and renoprotection in the long term. Our patients fell into 
histologic categories usually thought to be at risk of progression, and our data substantially confirm the 
results of Tang et al. It was emphasized that the conflicting effects obtained by MMF administration might 
reflect differences in the disease process, differences in MMF metabolism or varying responses to the 
immunosuppressive agent in different populations (2). We speculate that the presence of florid 
inflammatory processes, as documented by mesangial hyperplasia, intracapillary and extracapillary 
proliferation, and accumulation of leukocytes in the capillary lumina may be prerequisites for a response to 
the immunosuppressive therapy in IgAN, proteinuria being a uniform expression of both florid 
inflammatory and sclerotic changes. Cyclophosphamide proved to be effective in preserving renal function 
in the long run in these cases (3). However, infertility and malignancies (especially in the long-term 
treatment) in the young patient, and leukopenia and infections in the elderly, make this treatment 
unappealing and the advent of effective and safer forms of management more than welcome. A recent 
randomized controlled trial in patients with normal or slightly reduced renal function failed to demonstrate 
a greater efficacy of low-dose azathioprine added to steroids compared with steroids alone (11). However, 
the effects of azathioprine in high-risk patients, similar to the cohort of the present study, is still under the 
evaluation of the same multicenter research group. The short courses of therapy with steroids and MMF 
that were prospectively administered in this open trial seemed to be as effective as cyclophosphamide in a 
subset of IgAN patients with florid inflammatory changes, renal impairment and major urinary 
abnormalities, possibly preventing subsequent progression toward renal failure. We believe there is still a 
rationale for promoting new controlled studies with large sample sizes and long follow-up duration on high-
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TABLE I BASELINE CHARACTERISTICS OF THE STUDY POPULATION 
 
 
TABLE II HISTOLOGIC FEATURES OF THE STUDY POPULATION 
 
 
TABLE III PATIENT CATEGORIES ACCORDING TO URINARY PROTEIN EXCRETION BEFORE AND AFTER 
TREATMENT 
 
 Fig. 1 - Serum creatinine (mg/dL) during the follow-up period. Follow-up (FU) duration: SL 85 months, SA 66, BR 43, CT 




Fig. 2 - Proteinuria (mg/day) during the follow-up (FU) period. Follow-up duration: SL 85 months, SA 66, BR 43, CT 46, 
LGM 90, MM 24, SM 24 and SC 30. Compared with baseline values, the decrease was significant at 6 months and at 
the end of follow-up (p<0.01, in both cases). 
 
 
Fig. 3 - Profile of glomerular filtration rate (eGFR-MDRD186, ml/min per 1.73 m2) during the follow-up (FU) period. 
Followup duration: SL 85 months, SA 66, BR 43, CT 46, LGM 90, MM 24, SM 24 and SC 30. Compared with baseline 
values, the increase was significant at 6 months (p<0.05). 
 
Fig. 4 - Red blood cells/high-power microscopic field (RBC/ HPMF) ×400 (number/μL) during the follow-up period. 
Followup (FU) duration: SL 85 months, SA 66, BR 43, CT 46, LGM 90, MM 24, SM 24 and SC 30. Compared with 
baseline values, the decrease was significant both at 6 months (p=0.01) and at the end of follow-up (p<0.01). 
